- Stocks
- Pharma & Healthcare
- Nectar Lifesciences
Nectar Lifesciences share price
NSE: NECLIFEPharma & HealthcareDrug Manufacturers - Specialty & Generic
Nectar Lifesciences at a glance
Nectar Lifesciences (NSE: NECLIFE) closed at ₹11.34 on 22 Oct 2026, down 0.09% on the day. With a market capitalisation of ₹220 Cr, it ranks 2209th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −50.3% in FY26. Over the past year the share price has fallen 16.5%. Its 52-week range is ₹9.30 (30 Mar 2026) to ₹22.40 (23 Dec 2025); the last close is 49.4% below the high. Promoters held 51.84% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹220 CrRank 2209 on NSE
- Price to book
- 0.31×FY26
- EPS (TTM)
- −₹13.40to Q4 FY26
- ROE
- −50.3%FY26
- ROCE
- −8.7%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 0.0%FY26
- Book value / share
- ₹29.97FY26
- 52-week high
- ₹22.4023 Dec 2025
- 52-week low
- ₹9.3030 Mar 2026
- 1-year return
- −16.5%
- RSI (14-day)
- 59.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.09% | +12.3% | +4.0% | +7.5% | −16.5% |
Nectar Lifesciences quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹359 Cr | ₹428 Cr | ₹454 Cr | ₹429 Cr | ₹281 Cr | ₹5 Cr | — | — |
| Revenue YoY | −8.8% | +7.6% | +0.5% | −2.5% | −21.9% | −98.8% | — | — |
| Net profit | ₹3 Cr | ₹6 Cr | ₹8 Cr | −₹130 Cr | −₹63 Cr | −₹176 Cr | ₹14 Cr | −₹68 Cr |
| Net profit YoY | +63.2% | +449.0% | +399.4% | −22,149.2% | −2,229.0% | −3,243.0% | +82.0% | — |
| Net margin | 0.8% | 1.3% | 1.7% | −30.3% | −22.5% | −3,520.2% | — | — |
| EPS | ₹0.13 | ₹0.25 | ₹0.35 | −₹5.80 | −₹2.82 | −₹7.84 | ₹0.64 | −₹3.38 |
Nectar Lifesciences financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,543 Cr | ₹1,669 Cr | ₹1,524 Cr | ₹1,684 Cr | ₹1,670 Cr | — |
| Operating profit | −₹59 Cr | ₹34 Cr | −₹42 Cr | ₹18 Cr | −₹162 Cr | — |
| Net profit | −₹73 Cr | ₹25 Cr | −₹24 Cr | ₹5 Cr | −₹114 Cr | — |
| EPS (₹) | −₹3.00 | ₹1.00 | −₹1.00 | ₹0.00 | −₹5.00 | — |
| Cash from operations | ₹21 Cr | ₹95 Cr | ₹134 Cr | ₹225 Cr | ₹169 Cr | — |
| Total debt | ₹128 Cr | ₹291 Cr | ₹226 Cr | ₹140 Cr | ₹60 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,062 Cr | ₹1,088 Cr | ₹1,065 Cr | ₹1,069 Cr | ₹956 Cr | ₹582 Cr |
Nectar Lifesciences shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 20 Jan 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.53% | 44.91% | 44.91% | 51.84% | 51.84% | 51.84% |
| Foreign institutions | 0.81% | 0.62% | 0.52% | 0.58% | 0.60% | 0.50% |
| Domestic institutions | 0.19% | 0.09% | 5.82% | 3.54% | 4.01% | 3.74% |
| Non-institutions | 54.44% | 54.37% | 48.73% | 44.01% | 43.52% | 43.89% |
Nectar Lifesciences vs peers
The listed Pharma & Healthcare companies nearest to Nectar Lifesciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NATHBIOGENNath Bio-Genes (India) | ₹132.60 | +0.76% | −23.0% | ₹252 Cr | 6.3 | — |
| BDHBDH Industries | — | — | — | ₹252 Cr | — | — |
| NECLIFENectar Lifesciences | ₹11.34 | −0.09% | −16.5% | ₹220 Cr | — | — |
| HANNAHHannah Joseph | — | — | — | ₹220 Cr | — | — |
| SYSCHEMSyschem (India) | — | — | — | ₹214 Cr | — | — |
| ACHYUTAchyut Health | — | — | — | ₹209 Cr | — | — |
| CORALABCoral Labs | — | — | — | ₹196 Cr | — | — |
Ask anything about Nectar Lifesciences
Pivot answers on the live chart with evidence you can check, and tests strategies against NECLIFE's own history. Try: “Why has NECLIFE moved over the last three months?” · “Backtest a 50-day moving-average crossover on NECLIFE over five years” · “Compare NECLIFE with NATHBIOGEN on margins and valuation”
Frequently asked questions about Nectar Lifesciences
What is the share price of Nectar Lifesciences today?
Nectar Lifesciences (NSE: NECLIFE) last closed at ₹11.34 on 22 Oct 2026. Its 52-week high is ₹22.40 and its 52-week low is ₹9.30.
What is the market cap of Nectar Lifesciences?
Nectar Lifesciences' market capitalisation is ₹220 Cr (₹220 Cr) at the 22 Oct 2026 close, ranking 2209th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Nectar Lifesciences?
Return on equity was −50.3% in FY26 and return on capital employed was −8.7% in FY26 (consolidated figures).
Is Nectar Lifesciences a debt-free company?
Nectar Lifesciences is close to debt-free: its debt-to-equity ratio was 0 in FY26.
How has Nectar Lifesciences stock performed over the last year?
Nectar Lifesciences' share price has fallen 16.5% over the past year, +7.5% over three months and +4.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Nectar Lifesciences?
As of 30 Jun 2026: promoters 51.84%, foreign institutions 0.50%, domestic institutions 3.74%, non-institutions 43.89%.
Who are Nectar Lifesciences' competitors?
The listed Pharma & Healthcare companies closest to Nectar Lifesciences by market cap are Nath Bio-Genes (India), BDH Industries, Hannah Joseph, Syschem (India), Achyut Health and Coral Labs.
Is Nectar Lifesciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Nectar Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NECLIFE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text